Treatment of Chagas’ Disease — Time Is Running Out 

September 3, 2015 at 3:22 pm

N Engl J of Medic Sept.1, 2015

EDITORIALS

J.H. Maguire

From Brigham and Women’s Hospital and Harvard Medical School, Boston

Highly successful public health interventions in Latin America and widespread migration from rural areas to cities and countries where Trypanosoma cruzi is not endemic have markedly reduced the number of persons who are chronically infected with the protozoan parasite.

However, 5 million to 6 million persons remain infected, and in at least 20% of these persons, chronic Chagas’ cardiomyopathy either is present or will develop.

These persons are at high risk for heart failure, arrhythmias, and other life-threatening complications. Current recommendations call for antitrypanosomal treatment for most infected persons, but until now there has not been a randomized, controlled trial of the effect of antiparasitic treatment on cardiac outcomes….

PDF

http://www.nejm.org/doi/pdf/10.1056/NEJMe1510170

Entry filed under: Antiparasitarios, Epidemiología, Infecciones parasitarias, Metodos diagnosticos. Tags: .

Randomized trial of benznidazole for chronic Chagas’ cardiomyopathy. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.


Calendar

September 2015
M T W T F S S
« Aug   Oct »
 123456
78910111213
14151617181920
21222324252627
282930  

Most Recent Posts


%d bloggers like this: